NORML

JANUARY 4, 2019

Separate provisions in the bill exclude cannabidiol from the federal definition of marijuana, permit VA doctors to authorize medical cannabis access to qualified patients, and remove undue federal barriers to clinical trial research to better assess the safety and efficacy of medical cannabis.

Legislation 125

Legislation Clinical Trials Research and Development Access 125

Cannabis Law Report

AUGUST 12, 2021

loss per share, during the same period in 2020 (after including non-cash share-based compensation expense of $11.4 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. million during the same period in 2020. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 40

Clinical Trials Data Patients THC 40

Cannabis Law Report

JULY 8, 2021

Following the execution of this work, cbdMD Therapeutics will perform the requisite toxicological studies with Ion Tox, a leading in vitro toxicology and ADME-PK testing company, to support the safety of the cannabinoids of interest.

Research and Development 85

Research and Development Pets Cannabinoids eCommerce 85

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. The search included studies through 11-May-2020. Search strategy. 18 years old).

Safety 52

Safety Cannabinoids Events Data 52

Project CBD

FEBRUARY 28, 2023

This was somewhat less than the nearly 37% decline seen in 2020. decline from 2020. Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. million on these products.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JULY 9, 2021

On November 3, 2020, Oregon became the first state to decriminalize psilocybin for recreational purposes. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. Id ; 21 CFR 312.1-10;

Law 81

Law Therapy Clinical Trials Research and Development 81

Cannabis Law Report

NOVEMBER 13, 2019

Pharma-grade cannabis is scarce in the world and Denmark has quickly stepped in to fill the niche, cultivating to EU GACP standards, adhering to patient safety, retailing in pharmacies, tracking every medical cannabis prescription, and making patient access affordable. The roadmap ahead includes clinical trials and more research in Denmark.

Clinical Trials 78

Clinical Trials Research and Development Cultivation Patients 78

Cannabis Law Report

JUNE 25, 2021

billion in 2020 to $1.61 The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. Global Skin Cancer Drugs Historic Market, 2015-2020, $ Billion. Skin Cancer Drugs Market Size And Growth.

Research and Development 65

Research and Development Therapy Pharmaceutical Clinical Trials 65

LifeCannMD

AUGUST 2, 2024

More clinical trials are needed to establish definitive efficacy and safety profiles. – Details: The research emphasized the need for controlled clinical trials to better understand the optimal dosages and strains. The study also noted that patients using medical cannabis had improved quality of life.

Clinical Trials 52

Clinical Trials Marijuana Research and Development Cannabinoids 52

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible.

Research and Development 124

Research and Development Data THC Clinical Trials 124

LifeCannMD

MAY 27, 2025

Sleep: What the Sleep Studies Reveal A groundbreaking 2020 study from the University of New Mexico analyzed sleep data from over 5,000 medical marijuana patients. After six months of microdosing marijuana (2mg THC + 2mg CBD twice daily), his pain went from an 8/10 to a 3/10, and he’s back to playing golf three times a week.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

Cannabis Law Report

OCTOBER 13, 2021

Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Key Priorities for 2020.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

MARCH 29, 2020

This “zero recall” standard, the team said, was attributed to the fact that their cannabis product standards with regard to food safety and health was high and involved documentation of over 100 pages. . These are the responsibility of the manufacturer. Setting Standards for Cannabis Research Studies . Originally published By: [link].

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

NOVEMBER 26, 2021

Can-Fite Ends Phase II COVID-19 Trial to Focus on Core Indications – In 2020, with the aim of developing a much-needed drug to treat manifestations of COVID-19, mainly the Cytokine Release Syndrome, Can-Fite initiated a Phase II COVID-19 study of its lead drug candidate, Piclidenoson, with patient enrollment in Israel and Europe.

Clinical Trials 40

Clinical Trials Research and Development Treatment Data 40

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). In 2020, Goldfinch Bio was named one of Fierce Biotech’s “Fierce 15” companies.

Clinical Trials 40

Clinical Trials Research and Development Data Patients 40

Cannabis Law Report

JUNE 7, 2021

Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the U.S. Food and Drug Administration (U.S.

Clinical Trials 49

Clinical Trials Research and Development Therapy Supply Chain 49

The Cannigma

AUGUST 26, 2021

percent), according to the United Nations World Drug Report for 2020.In In addition, a survey published in July 2020 found that 41% of Australians support cannabis legalization, and 37% are opposed. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. The Journal of Clinical Pharmacology 60.4 2020): 432-438. Hospital Pharmacy (2021): 0018578720985438.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 40

Clinical Trials Research and Development Data Business 40

Cannabis Law Report

FEBRUARY 9, 2022

Oregonians voted to set up a system that would allow the use of psilocybin in some therapies back in 2020 by passing ballot Measure 109. There are also draft rules on how facilitators will be trained to sit with people taking psilocybin to ensure safety. Just to be sure that … they are still safe and applicable.”.

Clinical Trials 52

Clinical Trials Microdosing Safety Conditions 52

Cannabis Law Report

OCTOBER 26, 2021

Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials. Dr. Chapman is a graduate of the Harvard Kennedy School, Cambridge, Massachusetts, in financial management (2020). About the Arthritis Foundation.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

MARCH 25, 2020

SAN DIEGO , March 24, 2020 /PRNewswire/ — Medical Marijuana, Inc. (OTC: One of Sapphire’s diagnostic tools is currently being evaluated in a clinical trial for its potential to diagnose pancreatic cancer. Medical Marijuana, Inc. Source: [link].

Research and Development 45

Research and Development Supply Chain Pharmaceutical Clinical Trials 45

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. The outlier is ACT which in 2020 legalised cannabis for recreational use. A recent study by Lintzeris et al.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

NOVEMBER 10, 2021

as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies. The NIH has contracted with a clinical research organization to conduct additional pre-clinical efficacy studies and procured a device to be used with the manufactured GMP drug product for preclinical and clinical studies.

Research and Development 40

Research and Development Chronic Pain Pharmaceutical Clinical Trials 40

The Joint Blog

JULY 25, 2020

hemp-CBD market alone could hit $22 billion by 2020 , which is a mind-blowing figure given that the estimated worth of the entire U.S FDA is the government agency that ensures the safety and quality of foods, drugs, cosmetics, and other like products marketed in the United States. It has been predicted that the U.S

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

SEPTEMBER 3, 2019

Sales generation from the facility is expected to begin in the first half of 2020, subject to receipt of certain local authorizations and a certification from the Therapeutic Goods Association of Australia. “We MediPharm Labs Australia received its cannabis manufacturing licence from the ODC under the Narcotics Drugs Act 1967 on May 21, 2019.

Pharmaceutical 45

Pharmaceutical Extraction Research and Development Supply Chain 45

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. The Journal of Clinical Pharmacology 60.4 2020): 432-438. [6] 5] Greger, Jessica, et al. “ Epilepsia 58.9

CBD 52

CBD THC Conditions Medicine 52

Veriheal

AUGUST 31, 2020

It brings us great pleasure to present the 10 winners of Veriheal’s Innovation in Cannabis Scholarship 2020. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . The post Veriheal’s Innovation in Cannabis Scholarship 2020 Winners appeared first on Cannabis Central. Nishtha Tripathi. School: George Washington University.

Research and Development 119

Research and Development Education Agriculture Patients 119

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. for various studies, including FDA-approved clinical trials.

DEA 98

DEA Research and Development Cultivation Supply Chain 98

Cannabis Law Report

JUNE 4, 2021

It seems completely backwards that an unregulated product that gets people “high” and is synthesized in a lab can be sold at gas stations and smoke shops but naturally derived Delta 9-THC must go through rigorous safety testing and can only be sold and handled by licensed companies.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

Cannabis Law Report

MAY 29, 2022

In 2020, Oregon became the first locale to decriminalize psilocybin and legalize it for therapeutic use on a statewide basis. Clinical Trials and Human Subject Protections. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects. 20, 2020), [link]. [8]

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

The Cannigma

MARCH 12, 2021

We’re not going to get over the fact that there’s not the same sort of clinical trial and that type of evidence for cannabis and cannabis treatments in the very near future for various reasons. And in my belief, it should be cannabis, because of the safety profile, number one.

Legalization 132

Legalization Patients Education Dispensary 132

Cannabis Law Report

AUGUST 30, 2019

Ballot initiative campaigns to approve adult-use and medical cannabis, respectively, moved closer to appearing on the 2020 ballot in Arizona and Idaho, while a similar effort to put the issue of adult-use cannabis to Ohio voters has met with legal challenges from the State Election Board. Governor Ducey (R-AZ) opposes legalization.

Banking 45

Banking Research and Development Legislation Programs 45

Cannabis Law Report

JULY 14, 2021

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. ImmunoFlex’s believes that the immune system changes observed in this clinical study are beneficial changes with the potential to improve immune system competence. federal law.

Research and Development 81

Research and Development Clinical Trials Events Treatment 81